Skip to main content
SpringerLink
Log in

Pricing, Regulation, and Competitiveness

Lessons for the US from the Japanese Pharmaceutical Industry

  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

This paper examines the nature of Japanese government regulation of pharmaceutical prices, and the impact of that regulation on the competitive performance of the Japanese industry. Possible implications for the reintroduction of pharmaceutical price controls in the US are also considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. US General Accounting Office. Prescription drugs: companies typically charge more in the United States than in Canada. GAO/HRD-92-110, September 1992

    Google Scholar 

  2. US Senate, Special Committee on Aging. Prescription drug prices: are we getting our money’s worth? (August 1989)

    Google Scholar 

  3. Chew R, Teeling-Smith G, Wells R. Pharmaceuticals in seven nations. London: Office of Health Economics, 1985

    Google Scholar 

  4. Johnson CA. MITI, MPT, and the telecom wars: how Japan makes policy for high technology. In: Johnson C, Tyson LD’A, Zysman J, editors. Politics and productivity: how Japan’s development strategy works. New York: Harper Business, 1989

    Google Scholar 

  5. Reich MR. Why the Japanese don’t export more pharmaceuticals: health policy as industrial policy. California Management Review 1990; 32: 124–150

    Google Scholar 

  6. Kogut B. Country capabilities and the permeability of borders. Strategic Management Journal 1991; 12: 33–47

    Article  Google Scholar 

  7. Porter ME. The competitive advantage of nations. New York: Free Press, 1990

    Google Scholar 

  8. Thomas LG. Spare the rod and spoil the industry: vigorous competition and vigorous regulation promote global competitive advantage. Working paper (May 1993)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Business, Emory University, 226 Rich Bldg, Atlanta, Georgia, 30322, USA

    Lacy Glenn Thomas III

Authors
  1. Lacy Glenn Thomas III
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomas, L.G. Pricing, Regulation, and Competitiveness. Pharmacoeconomics 6 (Suppl 1), 67–70 (1994). https://doi.org/10.2165/00019053-199400061-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199400061-00016

Keywords

Search

Navigation